This free script provided by
JavaScript Kit


Catalog #:

IN0087-10mg USD86.0
IN0087-50mg USD252.0

References for ODQ:

1. Haramis, G., Zhou, Z., Pyriochou, A., Koutsilieris, M., Roussos, C., and Papapetropoulos, A. cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines. Br J Pharmacol, 155: 804-813, 2008.

2. Davidson, M. and Keating, J. Oswestry Disability Questionnaire (ODQ). Aust J Physiother, 51: 270, 2005.

3. Cechova, S. and Pajewski, T. N. The soluble guanylyl cyclase inhibitor ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, dose-dependently reduces the threshold for isoflurane anesthesia in rats. Anesth Analg, 99: 752-757, table of contents, 2004.

4. Chan, S. L. and Fiscus, R. R. Guanylyl cyclase inhibitors NS2028 and ODQ and protein kinase G (PKG) inhibitor KT5823 trigger apoptotic DNA fragmentation in immortalized uterine epithelial cells: anti-apoptotic effects of basal cGMP/PKG. Mol Hum Reprod, 9: 775-783, 2003.

5. Rosenblum, W. I., Wei, E. P., and Kontos, H. A. Dilation of rat brain arterioles by hypercapnia in vivo can occur even after blockade of guanylate cyclase by ODQ. Eur J Pharmacol, 448: 201-206, 2002.

6. Zacharowski, K., Berkels, R., Olbrich, A., Chatterjee, P. K., Cuzzocrea, S., Foster, S. J., and Thiemermann, C. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med, 29: 1599-1608, 2001.

Certificate of Analysis/MSDS is available upon request with lot number

Home | Contact | Support | Privacy Policy, Terms Warranty | Apycom jQuery Menus